Treace Medical Concepts, Inc. (NASDAQ: TMCI) is a Healthcare company (Medical - Devices) with a market capitalization of $291M. The Maz Rating grades it against the other companies in its sector.
Treace Medical Concepts, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $4.44, Treace Medical Concepts, Inc. trades at 1.4x sales and 4.7x book value. Over the last twelve months it generated about $203M of revenue and a net loss of $56M. It runs a gross margin of 79.6%, an operating margin of -24.4% and a net margin of -27.4%. It shows return on equity of -75.9%, return on invested capital of -35.6% and a free cash flow yield of -6.4%. On the balance sheet: a debt-to-equity ratio of 1.21 and a current ratio of 2.58. Over the past 52 weeks the share price ranged from $1.17 to $5.44, with a beta of 1.56.
Treace Medical Concepts, Inc. does not currently pay a dividend.
9 Wall Street analyst ratings cover the stock: 3 Buy, 5 Hold and 1 Sell, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions. It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant. In addition, the company offers The IntelliGuide patient specific instrumentation provides patient-specific, 3D-printed cut guides, and a pre-operative plan for a complete picture of the deformity and correction. Further, it provides FastGrafter Autografter Harvesting System; SpeedRelease Guided Release Instrument; TriTome Triple-Edge Release Instrument; RazorTome 7mm Precision Osteotome; LapiTome Hooked Bone Removal Osteotome; GreatRelease Rapid MTP Release Instrument; CornerChisel Release Tool; NanoRasp MIS Bone Contouring Tool; FeatherRasp Rapid Bone Contouring Instrument; and Akinator Single-cut Akin Wedge Osteotomy tool. Additionally, the company offers biologics and wedges, such as Treace Allograft Wedges; and CortiFuse Flowable Cortical Fibers. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Treace Medical Concepts, Inc. (TMCI) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 20.8% / 30% · (Cash+Inv) / Mkt Cap (36m) 13.7% / 30% · Interest income / Revenue 0.80% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 20.8% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 13.7% / 33% · Receivables / Mkt Cap (36m) 10.4% / 49% · Interest income / Revenue 0.80% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 20.8% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 13.7% / 33.33% · Receivables / Mkt Cap (24m) 10.4% / 33.33% · Interest income / Revenue 0.80% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 20.0% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 25.3% / 33.33% · Receivables / Avg Assets (4Q) 17.9% / 33.33% · Interest income / Revenue 0.80% / 5% | Pass |
| FTSE | Debt / Total Assets 33.7% / 33.33% · (Cash+ST Inv) / Total Assets 22.2% / 33.33% · (Cash+Recv) / Total Assets 39.1% / 33.33% · Interest income / Revenue 0.80% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Treace Medical Concepts, Inc. (TMCI) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
Yes. Treace Medical Concepts, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 0.80% of each dividend: Treace Medical Concepts, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.